SUBSTANCE AND NON SUBSTANCE RELATED ADDICTION DISORDERS diagnosis and treatment (1).
Material type: TextPublication details: [S.l. : BENTHAM SCIENCE PUBLISHER, (c)2017.Description: 1 online resourceContent type:- text
- computer
- online resource
- 9781681083438
- RC564 .S837 2017
- COPYRIGHT NOT covered - Click this link to request copyright permission: https://lib.ciu.edu/copyright-request-form
Item type | Current library | Collection | Call number | URL | Status | Date due | Barcode | |
---|---|---|---|---|---|---|---|---|
Online Book (LOGIN USING YOUR MY CIU LOGIN AND PASSWORD) | G. Allen Fleece Library ONLINE | Non-fiction | RC564 (Browse shelf(Opens below)) | Link to resource | Available | ocn984523853 |
Browsing G. Allen Fleece Library shelves, Shelving location: ONLINE, Collection: Non-fiction Close shelf browser (Hides shelf browser)
Includes bibliographies and index.
FOREWORD ; PREFACE ; List of Contributors ; Section I: General Topics ; Neurobiology and Psycho-Social Basis for Addiction and Related Disorders ; KEY LEARNING POINTS; NEUROBIOLOGY OF ADDICTION AND REWARD PATHWAYS; PSYCHOSOCIAL FACTORS; ADVERSE CHILDHOOD EXPERIENCES (ACE); CONFLICT OF INTEREST; ACKNOWLEDGEMENTS ; REFERENCES; Urine Drug Screening (UDS) in the Management of Substance Use Disorders ; KEY LEARNING POINTS; CLINICAL VIGNETTE; DIAGNOSTIC CONSIDERATION; REASONS FOR OBTAINING AN UDS; URINE DRUG SCREENS; Types of Urine Drug Tests; Urine Drug Test as a Follow-up Tool
Urine Sample CollectionChain of Custody; Medication Interfering with UDS; SPECIAL CONSIDERATIONS; Opiate/Opioid Metabolism; Benzodiazepines; Untested Substances; Altered Pharmacokinetic and Pharmacodynamic Parameters; SUMMARY; PATIENT INFORMATION SHEET -- URINE DRUG SCREENS; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS ; REFERENCES; Genetics of Addiction ; KEY LEARNING POINTS; GENETICS OF ADDICTION; SUMMARY; PATIENT EDUCATION SHEET; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Dual Diagnosis ; KEY LEARNING POINTS; CLINICAL VIGNETTE; BACKGROUND; DIAGNOSTIC CONSIDERATIONS
TREATMENT CONSIDERATIONSTREATMENT OUTCOMES; SUMMARY; DUAL DIAGNOSIS -- PATIENT INFORMATION SHEET; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS ; REFERENCES; Pharmacologic Treatment for Psychiatric Disorders Associated with Substance Use Disorders: An Overview ; KEY LEARNING POINTS; INTRODUCTION; Benzodiazepines (Table 1); Antidepressants; Serotonin Syndrome; Syndrome Presentation; Treatment; SSRI Withdrawal Phenomenon; Atypical/Typical Antipsychotics; Dosing; Monitoring; Additional Monitoring Recommended; Other Side Effects; Extrapyramidal Side Effects (EPSE); Treatment of Early -- EPSE
Dystonias and PseudoparkinsonismAkathisia; Treatment of Tardive Dyskinesia; Neuroleptic Malignancy Syndrome (NMS); Mood Stabilizers; Anticonvulsants; Management of Insomnia; SUMMARY; PATIENT INFORMATION -- MEDICATIONS FOR SUBSTANCE USE DISORDERS; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS ; REFERENCES; Motivational Interviewing ; KEY LEARNING POINTS; BACKGROUND; PROCESS; MOTIVATION ENHANCEMENT; THE STAGES OF CHANGE; SUMMARY; MOTIVATIONAL INTERVIEW-PATIENT EDUCATION SHEET; CONFLICT OF INTEREST; ACKNOWLEDGEMENTS; REFERENCES; Section II: Substance-Related Addiction Disorders (Alphabetical)
Alcohol Use Disorders KEY POINTS; CLINICAL VIGNETTE; INTRODUCTION; Epidemiology; Etiology; Diagnosis; Non-Pharmacologic Interventions; Pathophysiology of Alcohol Use Disorders (AUD); PHARMACOTHERAPY FOR ALCOHOL USE DISORDERS (AUD); Management of Outpatient Alcohol Withdrawal; FDA Approved Medications for Alcohol Use Disorder 26.; Disulfiram (Antabuse) 19, 21, 27.; Naltrexone (Revia (PO), Vivitrol (IM)); Acamprosate (Campral) 21, 28, 30.; Combination Therapy; Non-FDA Approved Pharmacotherapies for AD; SUMMARY; CLINICAL VIGNETTE RESOLUTION; PROVIDER RESOURCES
COPYRIGHT NOT covered - Click this link to request copyright permission:
There are no comments on this title.